Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) have been given an average recommendation of “Buy” by the eleven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $66.00.
Several equities analysts have weighed in on MAZE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, BTIG Research reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, August 12th.
Get Our Latest Research Report on Maze Therapeutics
Maze Therapeutics Stock Performance
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Equities analysts anticipate that Maze Therapeutics will post -2.71 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the sale, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $717,675. This trade represents a 22.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. This represents a 59.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 140,674 shares of company stock valued at $3,904,707 in the last 90 days. 5.30% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Maze Therapeutics
Several institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Maze Therapeutics in the fourth quarter valued at approximately $39,000. Ameritas Investment Partners Inc. grew its holdings in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics during the fourth quarter valued at $43,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the second quarter worth $48,000.
About Maze Therapeutics
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Stories
- Five stocks we like better than Maze Therapeutics
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
